(Q36142777)

12 August 2017

Costs and quality of life of patients with multiple sclerosis in Europe (English)

1 reference

12 August 2017

0 references

1 reference

3

Lindgren P

1 reference

12 August 2017

Kobelt G

1

1 reference

12 August 2017

Berg J

series ordinal

2

1 reference

12 August 2017

Fredrikson S

series ordinal

4

1 reference

12 August 2017

Jönsson B

series ordinal

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

11 May 2006

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

12 August 2017

1 reference

12 August 2017

77

1 reference

12 August 2017

918-926

1 reference

12 August 2017

8

1 reference

The economic cost of multiple sclerosis in Sweden in 1994.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Measurement of health state utilities for economic appraisal

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

EuroQol--a new facility for the measurement of health-related quality of life

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

The friction cost method for measuring indirect costs of disease.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077637

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis

23 September 2018

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents

1 reference

12 December 2020

Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model

1 reference

12 December 2020

The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy

1 reference

12 December 2020

Disease steps in multiple sclerosis: a simple approach to evaluate disease progression

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.2006.090365

1 reference

12 August 2017

1 reference

12 August 2017

1 reference